Seaport Therapeutics and Hemab Therapeutics, both clinical-stage biotechs, filed for Nasdaq IPOs on Friday, April 10, 2026.123
Hemab Therapeutics aims to raise up to $100 million, developing antibody therapies for blood coagulation disorders like Glanzmann thrombasthenia (Phase 3-ready), Factor VII deficiency (Phase 2), and Von Willebrand Disease (Phase 1/2); underwriters include Goldman Sachs, Jefferies, and Evercore ISI; ticker COAG.245
Seaport Therapeutics focuses on neuropsychiatric disorders using its proprietary Glyph platform for oral therapies targeting depression and anxiety; underwriters include Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup, and Stifel.3
Sources:
1. https://www.youtube.com/shorts/6GIIOJhlPq0
2. https://www.renaissancecapital.com/IPO-Center/News/118229/Coagulation-disorder-biotech-Hemab-Therapeutics-files-for-a-$100-million-IP
3. https://www.investing.com/news/stock-market-news/seaport-therapeutics-files-for-proposed-ipo-432SI-4608484
4. https://www.renaissancecapital.com/Profile/COAG/Hemab-Therapeutics/IPO